Cardiometabolic Health: What It Means, Why It Matters, and How to Improve It

What Is Cardiometabolic Health?

Cardiometabolic health is a single term for the interlinked state of two systems that break down together: the cardiovascular system and the body's metabolic machinery. A person with optimal cardiometabolic health has normal blood pressure, blood glucose, blood lipids, and body composition, alongside healthy vascular function. Deterioration in any one of these domains tends to pull the others down through shared pathways including chronic low-grade inflammation, insulin resistance, endothelial dysfunction, and excess visceral adiposity.

The American Heart Association formalized a scoring approach in 2022 with Life's Essential 8, an update to the original Life's Simple 7 framework first published in 2010. The eight metrics are: diet quality, physical activity, nicotine exposure, sleep duration, body mass index, blood lipids, blood glucose, and blood pressure. Each is scored 0 to 100, and the composite average defines overall cardiovascular health status. Adding sleep was not cosmetic. Short sleep duration independently predicts hypertension, insulin resistance, and elevated C-reactive protein, and the 2022 revision reflected a decade of accumulating evidence. [1]

Cardiometabolic disease is not a single diagnosis. Clinicians and researchers use the term to describe a cluster that includes metabolic syndrome, type 2 diabetes, hypertension, atherosclerotic cardiovascular disease (ASCVD), and non-alcoholic fatty liver disease (NAFLD). These conditions co-occur far above chance. A person presenting with newly diagnosed type 2 diabetes has a 50 to 80% probability of also meeting criteria for hypertension or dyslipidemia, and roughly 40% meet full metabolic syndrome criteria at diagnosis. [2]

The Five Core Biomarkers Every Patient Should Track

Tracking five specific numbers gives a practical snapshot of cardiometabolic status. Each has a validated evidence-based target, and together they capture the major risk domains.

Fasting plasma glucose and HbA1c. The American Diabetes Association's 2024 Standards of Care recommend an HbA1c target of <7.0% for most non-pregnant adults with type 2 diabetes, with individualization for age, hypoglycemia risk, and comorbidities. [3] A fasting glucose of 100 to 125 mg/dL signals prediabetes. Roughly 96 million U.S. adults have prediabetes, and 80% do not know it, according to CDC surveillance data. [4]

LDL cholesterol. The 2019 ACC/AHA guideline on the management of blood cholesterol recommends an LDL-C target of <70 mg/dL for very-high-risk ASCVD patients, and <100 mg/dL for high-risk primary prevention. [5] Statin therapy remains first-line, with PCSK9 inhibitors (evolocumab, alirocumab) reserved for patients who cannot achieve targets despite maximally tolerated statin doses.

Blood pressure. The 2017 ACC/AHA hypertension guideline redefined hypertension as blood pressure at or above 130/80 mmHg and set a target of <130/80 mmHg for most adults at elevated cardiovascular risk. [6] Uncontrolled hypertension accelerates atherosclerosis, promotes left ventricular hypertrophy, and increases the risk of both stroke and chronic kidney disease.

Triglycerides and HDL-C. A fasting triglyceride level above 150 mg/dL combined with an HDL-C below 40 mg/dL in men (or below 50 mg/dL in women) is among the five diagnostic criteria for metabolic syndrome per the IDF/AHA/NHLBI 2009 joint statement. [7] Hypertriglyceridemia is a marker of hepatic overproduction of VLDL and correlates with insulin resistance.

Waist circumference. Visceral fat is metabolically active in ways subcutaneous fat is not. It secretes pro-inflammatory adipokines, promotes hepatic insulin resistance, and independently predicts cardiovascular events even when BMI is in the normal range. The IDF threshold for elevated waist circumference is 94 cm (37 inches) for European men and 80 cm (31.5 inches) for European women, with population-specific cuts for South Asian, East Asian, and other groups. [7]

How Insulin Resistance Connects the Dots

Insulin resistance is the metabolic defect that ties most cardiometabolic conditions together. When skeletal muscle, liver, and adipose tissue stop responding normally to insulin, the pancreas compensates with higher insulin secretion. Hyperinsulinemia then drives hypertension through sodium retention and sympathetic nervous system activation, pushes the liver toward excess VLDL production (raising triglycerides and lowering HDL), and promotes visceral fat deposition.

Over time, beta-cell exhaustion follows. The pancreas cannot sustain compensatory output. Postprandial glucose rises first, then fasting glucose, and eventually HbA1c climbs above the 6.5% diabetes threshold. [3] This progression from insulin resistance to prediabetes to type 2 diabetes typically takes 10 to 15 years, which is exactly the window where lifestyle and pharmacological intervention can interrupt the trajectory.

Visceral adipose tissue is not passive storage. It releases free fatty acids directly into the portal circulation, driving hepatic de novo lipogenesis, and it secretes tumor necrosis factor-alpha and interleukin-6, which worsen insulin signaling in distant tissues. Reducing visceral fat by even 5 to 10% of body weight measurably improves insulin sensitivity, lowers blood pressure, and reduces liver fat. [8]

GLP-1 Receptor Agonists: Cardiometabolic Data Beyond Weight Loss

GLP-1 receptor agonists have become central to cardiometabolic pharmacotherapy. Their effects span glycemic control, body weight, blood pressure, and direct cardiovascular event reduction.

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneously once weekly produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% for placebo (P<0.001). [9] That weight loss magnitude is clinically significant for every cardiometabolic biomarker listed above.

The SELECT trial (N=17,604) enrolled adults with a BMI of 27 or higher and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a median follow-up of 34.2 months (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001). [10] This was the first dedicated cardiovascular outcomes trial to show MACE reduction in a population defined by overweight/obesity rather than by diabetes. The finding changed how cardiologists and endocrinologists think about weight-management therapy.

Liraglutide 1.8 mg demonstrated cardiovascular benefit earlier in the LEADER trial (N=9,340), reducing MACE by 13% versus placebo in adults with type 2 diabetes and high cardiovascular risk (HR 0.87 to 95% CI 0.78 to 0.97, P=0.01 for superiority). [11] The benefit was driven mainly by reductions in cardiovascular death.

For type 2 diabetes specifically, the ADA 2024 Standards of Care state: "In patients with type 2 diabetes and established CVD or indicators of high CVD risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended to reduce cardiovascular events." [3] That language reflects Level A evidence and represents a shift from glucose-centric prescribing toward cardiometabolic risk reduction as the primary goal.

Cardiometabolic Risk in Women: Menopause and Hormonal Shifts

Women experience a measurable acceleration in cardiometabolic risk during the menopause transition. Before menopause, endogenous estrogen supports insulin sensitivity, promotes favorable lipid profiles (higher HDL, lower LDL), and limits visceral fat accumulation. As estradiol declines through perimenopause, each of those protective effects erodes.

The Study of Women's Health Across the Nation (SWAN) documented that the menopausal transition associates with a significant increase in visceral adiposity, LDL cholesterol, and fasting insulin independent of aging alone. [12] Women who transition to menopause before age 45 (early menopause) carry a roughly 50% higher risk of developing type 2 diabetes compared with women who transition after age 50, according to data published in the journal Menopause. [13]

Menopausal hormone therapy (MHT) using transdermal estradiol does not carry the same thrombotic risk as oral conjugated equine estrogen, and observational data suggest transdermal estradiol may preserve insulin sensitivity and reduce the progression to metabolic syndrome in early postmenopausal women. The Menopause Society (formerly NAMS) 2022 Position Statement supports MHT for symptomatic women under age 60 or within 10 years of menopause onset, with the best cardiovascular risk-to-benefit profile in that window. [14]

Testosterone and Cardiometabolic Health in Men

Low testosterone in men associates with insulin resistance, increased visceral fat, elevated triglycerides, and reduced HDL cholesterol, creating a cardiometabolic risk profile that overlaps almost exactly with metabolic syndrome. Hypogonadism and metabolic syndrome co-occur at rates well above chance: a cross-sectional analysis in the Journal of Clinical Endocrinology and Metabolism found that men with metabolic syndrome had testosterone levels averaging 2.5 nmol/L lower than men without the condition. [15]

Testosterone replacement therapy (TRT) in hypogonadal men with type 2 diabetes improves HbA1c, fasting glucose, and body composition in several randomized trials. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone treatment in hypogonadal men with pre-existing cardiovascular disease or high cardiovascular risk did not increase MACE rates (HR 0.96 to 95% CI 0.83 to 1.12) over a mean follow-up of 22 months, which addressed a longstanding safety concern. [16] The FDA updated TRT labeling in 2024 to reflect these data.

Clinicians should screen for hypogonadism in men with metabolic syndrome or type 2 diabetes using a morning total testosterone level. The Endocrine Society guideline defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL (10.4 nmol/L) on two separate morning measurements. [17]

The Role of Sleep in Cardiometabolic Disease

Sleep is now a scored domain in the AHA's Life's Essential 8 precisely because the evidence linking poor sleep to cardiometabolic risk is strong and dose-dependent. A meta-analysis of 15 prospective cohort studies (N=474,684) published in the European Heart Journal found that sleeping fewer than 6 hours per night associated with a 48% higher risk of developing or dying from coronary heart disease (RR 1.48 to 95% CI 1.22 to 1.80). [18]

The mechanisms are multiple. Sleep deprivation raises cortisol and catecholamine levels, increasing 24-hour blood pressure. It dysregulates ghrelin and leptin, driving caloric overconsumption by an estimated 300 to 550 kcal/day in sleep-restricted subjects compared with normal sleepers, based on data from controlled inpatient studies. [19] Obstructive sleep apnea (OSA), which itself causes fragmented sleep, independently causes insulin resistance, hypertension, and atrial fibrillation. Treating OSA with CPAP therapy lowers systolic blood pressure by approximately 2 to 3 mmHg on average and reduces nocturnal glucose variability in people with type 2 diabetes. [20]

The ADA 2024 Standards of Care added a formal recommendation to screen adults with type 2 diabetes for OSA and to treat it when identified, citing the downstream cardiometabolic benefits. [3] A sleep duration target of 7 to 9 hours per night for adults is the consensus recommendation from the American Academy of Sleep Medicine and the AHA. [1]

Diet Patterns with Proven Cardiometabolic Benefit

No single food or nutrient fixes cardiometabolic risk. Dietary patterns do. The two patterns with the strongest cardiometabolic evidence base are the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet.

The PREDIMED trial (N=7,447) showed that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced the incidence of MACE by 30% (HR 0.70 to 95% CI 0.54 to 0.92) compared with a low-fat control diet over a median follow-up of 4.8 years in adults at high cardiovascular risk. [21] The benefit appeared within the first year of follow-up.

DASH was designed specifically to lower blood pressure. In the original DASH trial, adherence to the DASH pattern reduced systolic blood pressure by 11.4 mmHg in participants with hypertension, a magnitude comparable to first-line antihypertensive monotherapy. [22] Combining DASH with sodium restriction to 1 to 500 mg per day produced systolic reductions of up to 8.9 mmHg even in normotensive adults.

Both patterns share structural features: high intake of vegetables, legumes, whole grains, nuts, and olive oil; moderate fish and poultry; and low intake of red meat, refined carbohydrates, and ultra-processed foods. Ultra-processed food consumption above 4 servings per day associated with a 62% higher risk of all-cause mortality in the NutriNet-Santé cohort (N=44,551), independent of overall diet quality scores. [23]

Physical Activity as Cardiometabolic Medicine

Exercise acts as a polypill for cardiometabolic health. A single bout of aerobic exercise improves insulin sensitivity for 24 to 48 hours through GLUT4 translocation in skeletal muscle, independent of weight change. Regular aerobic training reduces systolic blood pressure by an average of 4.9 mmHg, reduces LDL-C by approximately 5 mg/dL, raises HDL-C by 2 to 3 mg/dL, and reduces HbA1c by 0.6 to 0.7 percentage points in adults with type 2 diabetes. [24]

The 2018 Physical Activity Guidelines for Americans, endorsed by the AHA and ADA, recommend 150 to 300 minutes per week of moderate-intensity aerobic activity, plus muscle-strengthening activities on 2 or more days per week. [25] Resistance training is not optional for cardiometabolic patients. It preserves lean mass during caloric restriction and GLP-1-mediated weight loss, which matters because lean mass loss of more than 30% of total weight lost predicts weight regain and worsened insulin sensitivity after weight stabilization.

High-intensity interval training (HIIT) produces cardiometabolic improvements comparable to moderate-intensity continuous training in roughly half the time, based on a systematic review and meta-analysis of 50 trials (N=1,334) published in the British Journal of Sports Medicine. [26] Three 20-minute HIIT sessions per week are physiologically equivalent to five 40-minute moderate-intensity sessions for most cardiometabolic endpoints.

Mental Health and Cardiometabolic Risk: A Two-Way Street

Depression and cardiometabolic disease share bidirectional causality. Depression approximately doubles the risk of developing type 2 diabetes, with a pooled relative risk of 1.60 (95% CI 1.37 to 1.88) across 9 prospective cohort studies. [27] Type 2 diabetes, conversely, increases the risk of depression by approximately 15 to 24% compared with people without diabetes, after controlling for confounders.

The mechanisms run in both directions. Depression raises cortisol and inflammatory cytokines, drives physical inactivity, disrupts sleep, and increases appetite for high-calorie foods. Hyperglycemia and the burden of chronic disease management, in turn, worsen depressive symptoms and erode the motivation needed for self-management behaviors.

Screening for depression using a validated tool such as the PHQ-9 is recommended annually for all adults with type 2 diabetes by the ADA 2024 Standards of Care. [3] Integrated behavioral health models, where mental health support is embedded in cardiometabolic care, show measurably better glycemic and weight outcomes compared with usual care alone. The COMPASS trial demonstrated that a systematic approach to depression care in patients with diabetes reduced PHQ-9 scores by 5.1 points more than usual care over 12 months and simultaneously improved HbA1c by 0.4 percentage points. [28]

Putting It Together: A Practical Monitoring Schedule

Optimal cardiometabolic management requires scheduled biomarker tracking, not symptom-driven testing. Most cardiometabolic diseases are silent until they cause an event.

For adults with type 2 diabetes or metabolic syndrome, the ADA recommends:

• HbA1c: every 3 months until at goal, then every 6 months
• Fasting lipid panel: annually, or every 1 to 2 years if stable and at target
• Blood pressure: at every clinical encounter
• Urine albumin-to-creatinine ratio: annually, to detect early diabetic kidney disease
• Liver enzymes and liver fibrosis assessment (FIB-4 index): every 1 to 2 years given the high co-prevalence of NAFLD in type 2 diabetes [3]

For patients starting a GLP-1 receptor agonist for weight management or cardiovascular risk reduction, a baseline cardiometabolic panel including fasting glucose, HbA1c, full lipid panel, blood pressure, and waist circumference allows objective tracking of response. Reassess at 12 weeks and 6 months. If weight loss at 16 weeks is <5% of baseline body weight on the maximum tolerated dose, current ADA and Obesity Society guidelines suggest reassessing the treatment plan, which may include switching agents or adding a second mechanism such as SGLT-2 inhibitor therapy. [3]